ArticleJournal of translational medicine2022

miR-1297 sensitizes glioma cells to temozolomide (TMZ) treatment through targeting adrenomedullin (ADM).

Zongze He et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.